Mirati Therapeutics, Inc. (MRTX) News
Filter MRTX News Items
MRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRTX News Highlights
- MRTX's 30 day story count now stands at 4.
- Over the past 15 days, the trend for MRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AMGN and LUNG are the most mentioned tickers in articles about MRTX.
Latest MRTX News From Around the Web
Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for LumakrasPer the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval. |
Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesOn December 18, 2023, Jamie Christensen, EVP & Chief Scientific Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), executed a sale of 2,387 shares in the company. |
Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)In a recent transaction on December 13, 2023, Benjamin Hickey, the Executive Vice President and Chief Commercial Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), sold 2,220 shares of the company. |
Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges(Bloomberg) -- Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First TimeRaimondo Vows ‘Stronges |
3 Resilient Stocks with Massive Potential to Boost Your WealthThese three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. |
3 Biotech Stocks That Could Boom or Bust by 2025Biotech stocks are popular with investors because they sometimes provide tremendous rewards. |
UPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingMirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer. The European Medicine Agency's committee backed Krazati following a re-examination of the drug the panel had declined to back for authorization in July, saying the requirements for conditional support were not fulfilled, which Mirati had disagreed with. Krazati received the U.S. Food and Drug Administration's accelerated approval last year and also the UK health regulator's authorization earlier this month. |
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedureMirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. |
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss ExpectationsMirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses. |
Paramount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cutsBofA on Monday downgraded media conglomerate Paramount Global (NASDAQ:PARA) by two notches - to Underperform from Buy - with a price target of $9.00 (from $32.00). |